Crizotinib Continuation Clinical Study

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 27, 2021

Primary Completion Date

March 21, 2028

Study Completion Date

March 21, 2028

Conditions
NSCLCALCLIMT
Interventions
DRUG

crizotinib

crizotinib oral treatment

Trial Locations (13)

100

National Taiwan University Hospital, Taipei

20900

ASST Monza, Monza

100021

Cancer Hospital Chinese Academy of Medical Science, Beijing

100142

Beijing Cancer Hospital, Beijing

130028

Jilin Cancer Hospital, Changchun

197022

"Limited Liability Company EuroCityClinic", Saint Petersburg

200030

Shanghai Chest Hospital, Shanghai

310003

The First Affiliated Hospital of College of Medicine,Zhejiang University, Hangzhou

350014

Fujian Province Oncology Hospital, Fuzhou

510060

Sun Yat-Sen University Cancer center, Guangzhou

510120

The First Affiliated Hospital of Guangzhou Medical University., Guangzhou

610041

West China Hospital of Sichuan University, Wuhou District

460-0001

National Hospital Organization Nagoya Medical Center, Nagoya

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY